Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
65.20
+3.77 (6.14%)
At close: Mar 6, 2026, 4:00 PM EST
66.43
+1.23 (1.89%)
After-hours: Mar 6, 2026, 6:27 PM EST
Dianthus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 3.08 | 6.24 | 2.83 | 6.42 | 1.48 |
| Revenue Growth (YoY) | -42.64% | 120.63% | -55.96% | 334.76% | - |
| Gross Profit | 3.08 | 6.24 | 2.83 | 6.42 | 1.48 |
| Selling, General & Admin | 31.21 | 24.99 | 18.16 | 6.74 | 1.96 |
| Research & Development | 112.18 | 83.11 | 32.84 | 29.38 | 12.61 |
| Operating Expenses | 143.39 | 108.1 | 51 | 36.12 | 14.56 |
| Operating Income | -140.31 | -101.86 | -48.17 | -29.71 | -13.09 |
| Interest & Investment Income | 12.82 | 17.37 | 4.76 | 1.15 | 0 |
| Currency Exchange Gain (Loss) | -0.03 | -0.06 | -0.09 | 0.14 | -0.03 |
| Other Non Operating Income (Expenses) | -0.95 | -0.55 | -0.06 | -0.05 | - |
| EBT Excluding Unusual Items | -128.47 | -85.12 | -43.56 | -28.48 | -13.11 |
| Gain (Loss) on Sale of Investments | 2.12 | 0.15 | - | - | - |
| Pretax Income | -126.35 | -84.97 | -43.56 | -28.48 | -13.11 |
| Net Income | -126.35 | -84.97 | -43.56 | -28.48 | -13.11 |
| Net Income to Common | -126.35 | -84.97 | -43.56 | -28.48 | -13.11 |
| Shares Outstanding (Basic) | 36 | 33 | 5 | 1 | 4 |
| Shares Outstanding (Diluted) | 36 | 33 | 5 | 1 | 4 |
| Shares Change (YoY) | 28.44% | 546.44% | 489.48% | -78.17% | - |
| EPS (Basic) | -3.49 | -2.55 | -8.45 | -32.57 | -3.27 |
| EPS (Diluted) | -3.49 | -2.55 | -8.45 | -32.57 | -3.27 |
| Free Cash Flow | -109.63 | -78.29 | -36.97 | -29.21 | -9.94 |
| Free Cash Flow Per Share | -3.03 | -2.35 | -7.17 | -33.41 | -2.48 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -4558.41% | -1633.75% | -1704.67% | -462.91% | -886.59% |
| Profit Margin | -4104.78% | -1362.78% | -1541.22% | -443.76% | -888.14% |
| Free Cash Flow Margin | -3561.63% | -1255.57% | -1308.24% | -455.18% | -673.24% |
| EBITDA | -140.2 | -101.77 | -48.11 | -29.68 | - |
| D&A For EBITDA | 0.11 | 0.1 | 0.07 | 0.03 | - |
| EBIT | -140.31 | -101.86 | -48.17 | -29.71 | -13.09 |
| Revenue as Reported | 3.08 | 6.24 | 2.83 | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.